US › Healthcare

Design Therapeutics Inc (DSGN)

US · Healthcare · Biotechnology

$13.20+3.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-17.6M
Profit YoY
+0.4%
EPS
$-0.29
EPS estimate
$-0.33

EPS came in at -0.29 against a street estimate of -0.33 — a beat of 12.1%.

Key statistics

Market cap
$760.7M
Forward P/E
0.0
P/B
3.49
Book value
$3.49
EPS (TTM)
$-1.20
52-week high
$17.25
52-week low
$3.90
50-day MA
$12.34
200-day MA
$10.62
Beta
1.59

Analyst view

Analysts rate Design Therapeutics Inc a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $21.00.

Shareholding

Insiders
31.93%
Institutions
62.23%

Largest institutional holders

FundStake
SR ONE CAPITAL MANAGEMENT, LP10.45%
RA Capital Management, LLC4.76%
Point72 Asset Management, L.P.4.36%
Baker Bros Advisors LP4.14%
BlackRock Inc3.42%
Logos Global Management LP3.12%
Driehaus Capital Management LLC2.79%
Vivo Capital, LLC2.58%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Design Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.